Sugi Predict

Sugi Predict / Compounds / SCHEMBL6450178

SCHEMBL6450178

SCHEMBL6450178

CC(=O)c1cc(F)ccc1OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.60
▸ MAPT P10636 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ CYP2C19 P33261 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ NPC1 O15118 1/20 0.55
▸ LMNA P02545 1/20 0.54
▸ MAOB P27338 2/20 0.54
▸ SGMS2 Q8NHU3 1/20 0.54
▸ MRGPRX4 Q96LA9 1/20 0.53
▸ FOLH1 Q04609 1/20 0.52
▸ BRD4 O60885 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29707531 1.00 LRRK2 (0.60) LRRK2MAPTL3MBTL1CYP2C9CYP2C19
SCHEMBL1041517 0.88 MAOB (0.61) LRRK2MAPTL3MBTL1CYP2C9CYP2C19
SCHEMBL30956730 0.88 MAOB (0.61) LRRK2MAPTL3MBTL1CYP2C9CYP2C19
SCHEMBL1646699 0.88 FOLH1 (0.67) LRRK2MAPTL3MBTL1NPC1LMNA
SCHEMBL12677013 0.86 SMN1; SMN2 (0.50) LRRK2MAPTL3MBTL1SMN1; SMN2MEN1
SCHEMBL17040660 0.86 FFAR4 (0.60) LRRK2MAPTL3MBTL1SMN1; SMN2KMT2A
SCHEMBL5273674 0.85 LRRK2 (0.52) LRRK2MAPTL3MBTL1CYP2C9CYP2C19
SCHEMBL5273678 0.85 LRRK2 (0.52) LRRK2MAPTL3MBTL1CYP2C9CYP2C19
SCHEMBL9431930 0.85 L3MBTL1 (0.65) LRRK2MAPTL3MBTL1CYP2C9CYP2C19
SCHEMBL22454501 0.85 MAOB (0.58) MEN1KMT2ALMNAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300973-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME BIOFRONT THERAPEUTICS (BEIJING) CO. LTD. (CN) 2024-09-12 — — US disclosed
US-20240109897-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2024-04-04 — — US disclosed
CN-117157296-A Modulators of FPR1 and methods of use thereof 首都医科大学附属北京天坛医院 2023-12-01 — — CN disclosed
WO-2023109213-A1 METHOD FOR PREPARING CHIRAL AMINE COMPOUND 深圳先进技术研究院 2023-06-22 — — WO disclosed
US-11584759-B2 Macrocyclic kinase inhibitor HITGEN INC. (CN) 2023-02-21 — — US disclosed
US-11584759-B2 Macrocyclic kinase inhibitor HITGEN INC. (CN) 2023-02-21 — — US disclosed
CN-114805387-A Modulators of FPR1 and methods of use thereof 百放英库医药科技(北京)有限公司 2022-07-29 — — CN disclosed
EP-3783000-B1 MACROCYCLIC KINASE INHIBITOR HITGEN INC (CN) 2022-07-06 — — EP disclosed
EP-3783000-B1 MACROCYCLIC KINASE INHIBITOR HITGEN INC (CN) 2022-07-06 — — EP disclosed
CN-110386945-B Macrocyclic kinase inhibitor 广州白云山医药集团股份有限公司白云山制药总厂 2021-09-28 — — CN disclosed
US-20210147443-A1 MACROCYCLIC KINASE INHIBITOR HITGEN INC. (CN) 2021-05-20 — — US disclosed
US-20210147443-A1 MACROCYCLIC KINASE INHIBITOR HITGEN INC. (CN) 2021-05-20 — — US disclosed
EP-3783000-A1 MACROCYCLIC KINASE INHIBITOR Hitgen Inc. (CN) 2021-02-24 — — EP disclosed
EP-3783000-A1 MACROCYCLIC KINASE INHIBITOR Hitgen Inc. (CN) 2021-02-24 — — EP disclosed
WO-2019201282-A1 MACROCYCLIC KINASE INHIBITOR 成都先导药物开发股份有限公司 2019-10-24 — — WO disclosed
WO-2019201282-A1 MACROCYCLIC KINASE INHIBITOR 成都先导药物开发股份有限公司 2019-10-24 — — WO disclosed
EP-3107900-B1 5-BENZYLISOQUINOLEINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES SERVIER LAB (FR) 2017-11-15 — — EP disclosed
WO-2015124877-A1 DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES LES LABORATOIRES SERVIER (FR) 2015-08-27 — — WO disclosed
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 — — US disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147443-A1 MACROCYCLIC KINASE INHIBITOR MAP3K20, TNK2, NTRK1 LRRK2 451/4885MAPT 2492/4885L3MBTL1 1023/4885
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC LRRK2 2944/4885MAPT 2805/4885L3MBTL1 4366/4885
US-20240300973-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME FPR1, FPR2, FPR3 LRRK2 2910/4885MAPT 4595/4885L3MBTL1 4027/4885
US-20240109897-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME FPR1, FPR2, FPR3 LRRK2 2910/4885MAPT 4595/4885L3MBTL1 4027/4885
US-11584759-B2 Macrocyclic kinase inhibitor MAP3K20, TNK2, NTRK1 LRRK2 451/4885MAPT 2492/4885L3MBTL1 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.